Log in

Relevant bibliographies by topics / Chemotherapy of cancer / Journal articles

To see the other types of publications on this topic, follow the link: Chemotherapy of cancer.

Journal articles on the topic 'Chemotherapy of cancer'

Author: Grafiati

Published: 4 June 2021

Last updated: 14 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Chemotherapy of cancer.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Armini, Ni ketut alit, Masfin Muhayanah, and Aria Nastiti. "DIARRHEA INCIDENT IN CERVICAL CANCER PATIENTS POST CHEMOTHERAPY TREATMENT." Jurnal NERS 11, no. 1 (April 1, 2016): 106. http://dx.doi.org/10.20473/jn.v11i12016.106-111.

Full text

Abstract:

Backgrounds : Cervical cancer is second most diseases suffered by women. Chemotherapy is primary treatment for cervical cancer. Chemotherpy has some side effect, and one of them is diarrhea. Diarrhea make cervical cancer suffered more. The purpose of this research was to analyze the correlation of factor’s that cause diarrhea on cervical cancer.Methods : This research uses descriptive analitic method with retrospective design. The population in this research is all patients who had post first chemotherapy. Sample in this study were 21 respondents, with purposive sampling. Variable independent were type of chemotherapy drugs, character of chemotheraphy, staging, stress and dietary. Variable dependent was diarrhea. Data collected using quesionare. Data were analyzed using chi square test with level of significant α≤0,05.Results : The result of the study reveals that type of the chemotherapy drug p:0,598, character of chemotheraphy p:0,336,. Staging has correlation with diarrhea significant of p:0,022. Stress and dietary analysisis presented p:0,00. It means that there was significant correlation with diarrhea.Conclusion : It can be concluded that diarrhea incident related to staging, stress and dietarry. There‘s no correlation between type of chemotherapy drug, character of chemotheraphy with diarrhea Further studies should give health education about dietary causing diarrhea, chemotherapy procedural and sides effect’s, increase supports for patient with cervical cancer. Keyword: Cervical Cancer, Chemotherapy, Diarrhea.

APA, Harvard, Vancouver, ISO, and other styles

2

Jacobs, Charlotte. "Cancer chemotherapy." International Journal of Radiation Oncology*Biology*Physics 12 (November 1986): 78. http://dx.doi.org/10.1016/0360-3016(86)90477-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Gudas, Stephen A. "Cancer Chemotherapy." Rehabilitation Oncology 13, no. 2 (1995): 12–20. http://dx.doi.org/10.1097/01893697-199513020-00010.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Kardinal, Carl G. "Cancer chemotherapy." Postgraduate Medicine 77, no. 6 (May 1985): 165–74. http://dx.doi.org/10.1080/00325481.1985.11698989.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Shalaby, Waleed S. W., Heidi J. Gray, and John J. Mikuta. "Cancer Chemotherapy." Postgraduate Obstetrics & Gynecology 24, no. 13 (June 2004): 1–7. http://dx.doi.org/10.1097/00256406-200406300-00001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Anderson, Philip O. "Cancer Chemotherapy." Breastfeeding Medicine 11, no. 4 (May 2016): 164–65. http://dx.doi.org/10.1089/bfm.2016.0042.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Zeller, John L. "Cancer Chemotherapy." JAMA 299, no. 22 (June 11, 2008): 2706. http://dx.doi.org/10.1001/jama.299.22.2706.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Owen, L. "Cancer chemotherapy." Veterinary Record 118, no. 13 (March 29, 1986): 364–66. http://dx.doi.org/10.1136/vr.118.13.364.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Berman, Arlene, Laura Chisholm, Maria de Carvalho, Joan A. Piemme, and Catherine Rice Gorrell. "Cancer Chemotherapy." Cancer Nursing 16, no. 2 (April 1993): 145???160. http://dx.doi.org/10.1097/00002820-199304000-00010.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Chisholm, Laura G., Arlene R. Berman, Maria de Carvalho, and Catherine Rice Gorrell. "Cancer Chemotherapy." Cancer Nursing 16, no. 3 (June 1993): 237???246. http://dx.doi.org/10.1097/00002820-199306000-00010.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Lake, Tricia, and Jean Jenkins. "Cancer Chemotherapy." Cancer Nursing 16, no. 6 (December 1993): 486???497. http://dx.doi.org/10.1097/00002820-199312000-00010.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Knezevic, Claire E., and William Clarke. "Cancer Chemotherapy." Therapeutic Drug Monitoring 42, no. 1 (February 2020): 6–19. http://dx.doi.org/10.1097/ftd.0000000000000701.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Gerry, Edwina. "Cancer chemotherapy." Nurse Education Today 11, no. 4 (August 1991): 322–23. http://dx.doi.org/10.1016/0260-6917(91)90112-n.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

A Tawfik, Hatem. "Meta-Analysis and Randomized Trials: Chemotherapy for Advanced Pancreatic Cancer." Endocrinology and Disorders 1, no. 2 (August 10, 2017): 01–03. http://dx.doi.org/10.31579/2640-1045/009.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Henderson, Craig. "Chemotherapy treatments: chemotherapy for breast cancer." International Journal of Radiation Oncology*Biology*Physics 24 (January 1992): 93–94. http://dx.doi.org/10.1016/0360-3016(92)90075-s.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Tsushima, Tomoyasu. "S14-3 Intravesical chemotherapy for superficial bladder cancer(Symposium 14「Management of Superficial Bladder Cancer」)." Japanese Journal of Urology 97, no. 2 (2006): 178. http://dx.doi.org/10.5980/jpnjurol.97.178_1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

McVie, Gordon, Harvey Schipper, and Karol Sikora. "Cancer 2025: Chemotherapy." Expert Review of Anticancer Therapy 4, sup1 (June 2004): S43—S50. http://dx.doi.org/10.1586/14737140.4.5.s43.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Silberner, Joanne. "Resisting Cancer Chemotherapy." Science News 131, no. 1 (January 3, 1987): 12. http://dx.doi.org/10.2307/3971666.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Schlag, Peter. "Continuous Cancer Chemotherapy." International Journal of Technology Assessment in Health Care 1, no. 2 (April 1985): 343–51. http://dx.doi.org/10.1017/s026646230000012x.

Full text

Abstract:

In the last decade, the incidence of mortality caused by malignant disease has risen. Cancer related deaths are more frequent than those caused by infections or accidents, exceeded only by heart and vascular diseases. In most cases, it is not the primary tumor that kills patients, but its metastatic spread: metastases have a fatal outcome more than 90% of cases (1). By the time metastases have occurred, cure is rarely obtained through surgical procedures. Local radiotherapy to distant metastases is also rarely successful in the treatment of disseminated malignancies. Most patients with metastatic disease need a palliative systemic treatment, which means cytotoxic cancer chemotherapy. Its objective is to destroy cancer cells. Systemic chemotherapy has become standard in the last decades for most disseminated malignancies (1).

APA, Harvard, Vancouver, ISO, and other styles

20

Salvage, A. V., and B. Quinn. "Cancer and chemotherapy." BMJ 339, aug24 1 (August 24, 2009): b2875. http://dx.doi.org/10.1136/bmj.b2875.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Allison, Susan J. "Colorectal Cancer Chemotherapy." Nature Reviews Gastroenterology & Hepatology 6, no. 5 (May 2009): 257. http://dx.doi.org/10.1038/nrgastro.2009.48.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Christian, J., and H. Thomas. "Ovarian cancer chemotherapy." Cancer Treatment Reviews 27, no. 2 (April 2001): 99–109. http://dx.doi.org/10.1053/ctrv.2001.0219.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Gargan, Thomas J., Steven E. Come, and Paul R. Satwicz. "Breast Cancer Chemotherapy." Plastic and Reconstructive Surgery 75, no. 3 (March 1985): 430–34. http://dx.doi.org/10.1097/00006534-198503000-00027.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Gibbons, Robert P. "Prostate cancer. Chemotherapy." Cancer 60, S3 (August 1, 1987): 586–88. http://dx.doi.org/10.1002/1097-0142(19870801)60:3+<586::aid-cncr2820601525>3.0.co;2-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Gill, S., R. R. Thomas, and R. M. Goldberg. "Colorectal cancer chemotherapy." Alimentary Pharmacology & Therapeutics 18, no. 7 (September 19, 2003): 683–92. http://dx.doi.org/10.1046/j.1365-2036.2003.01735.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

McArthur, Heather L., and Clifford A. Hudis. "Breast Cancer Chemotherapy." Cancer Journal 13, no. 3 (May 2007): 141–47. http://dx.doi.org/10.1097/ppo.0b013e318074dc6f.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Lokich, Jacob J. "Improved cancer chemotherapy." Postgraduate Medicine 87, no. 2 (February 1990): 239–46. http://dx.doi.org/10.1080/00325481.1990.11704570.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Kaplan, Michael J., Michael E. Johns, and Robert W. Cantrell. "Chemotherapy for Salivary Gland Cancer." Otolaryngology–Head and Neck Surgery 95, no. 2 (September 1986): 165–70. http://dx.doi.org/10.1177/019459988609500206.

Full text

Abstract:

Because of the scarcity of such lesions, little is known about the efficacy of chemotherapy for advanced salivary gland cancers. Although surgery and irradiation are the mainstays of treatment, patients with recurrent tumors and those with unresectable or metastatic cancer are not candidates for this usual approach. Ten patients with recurrent, metastatic, or unresectable salivary gland tumors were treated with combination chemotherapy, primarily with cisplatin, doxorubicin hydrochloride (Adriamycin), and cyclophosphamide, or cisplatin with 5-fluorouracil. In patients whose tumors exhibited no response, second-line drugs were used. The overall response rate was 50%—with one complete response—but the duration of response was short. This report contributes to the growing data base that demonstrates definite chemosensitivity of these tumors. To date, 116 patients have been reviewed. Adenocarcinoma-like cancers respond best to cisplatin, doxorubicin hydrochloride, and 5-fluorouracil. Highgrade mucoepidermoid carcinoma may show a sensitivity similar to that of squamous cell carcinoma. Multi-institutional protocols need to be developed to assess the roles of adjuvant and palliative chemotherapy in the treatment of salivary gland cancer.

APA, Harvard, Vancouver, ISO, and other styles

29

Zucali, Roberto, Roberto Doci, Rado Kenda, Laura Lozza, Silvia Tana, and Francesca Valvo. "Radio-Chemotherapy of Anal Cancer." Tumori Journal 84, no. 2 (March 1998): 247–49. http://dx.doi.org/10.1177/030089169808400224.

Full text

Abstract:

Conventional treatment of anal cancer has been the demolitive Miles operation for decades. Radiotherapy has been utilized in a limited number of centers for early cancers only. Radio-chemotherapy has become the treatment of choice for all stages of anal cancer after the first experiences by the group of Detroit and after the confirmation of successful results by many other centers. Infusional chemotherapy (5-FU and Mitomycin C or CDDP) and concurrent irradiation are able to achieve local control in more than 80% of patients. Surgery currently represents a rescue treatment for partial responders or in relapsing patients. A brief review of the literature and the experience at the Istituto Tumori in Milano are presented.

APA, Harvard, Vancouver, ISO, and other styles

30

Moha, Rico. "Chemotherapy medication of Vincristine and Vinblastine." Cancer Research and Cellular Therapeutics 1, no. 1 (December 8, 2017): 01–02. http://dx.doi.org/10.31579/2640-1053/007.

Full text

Abstract:

Cancers treated with Vincristine and vinblastine include: acute leukemia, Hodgkin's and non- Hodgkin's lymphoma, neuroblastoma, rhabdomyosarcoma, Ewing's sarcoma, Wilms' tumor, multiple myeloma, chronic leukemias, thyroid cancer, brain tumors, non-small cell lung cancer, bladder cancer, melanoma, and testicular cancer andIt is also used to treat some blood disorders. It is given by injection into a vein. Vincristine and vinblastine exhibit differential activity against tumors and normal tissues. In this work, a number of cultured cell lines were assayed for their sensitivity to the antiproliferative and cytotoxic effects of the two drugs following short-term (4 hr) or during continuous exposures. Differential activity was not seen when cells were subjected to continuous exposures. The concentrations of Vincristine and vinblastine, respectively, that inhibited growth rates by 50% were: mouse leukemia L1210 cells, 4.4 and 4.0 nw; mouse lymphoma S49 cells, 5 and 3.5 nM; mouse neuroblastoma cells, 33 and 15 nw; HeLa cells, 1.4 and 2.6 nw; and human leukemia HL-60 cells, 4.1 and 5.3 nM. In contrast, differential toxicity was seen when cells were subjected to 4-hr exposures and transferred to drug-free medium: the 50% growth-inhibitory concentrations for Vincristine and vinblastine, respectively, for inhibition (a) of proliferation of L1210 cells were 100 and 380 nM and of HL-60 cells were 23 and 900 nM and (b) of colony formation of L1210 cells were 6 and >600 nM and of HeLa cells were 33 and 62 nM. Uptake and release of [3H]- vincristine and [3H]vinblastine were examined in L1210 cells under the conditions of growth experiments. Uptake of both drugs was dependent on the pH of culture media, and signifi cantly greater amounts of [3H]vinblastine than of [3H]vincristine were associated with cells after 4-hr exposures to equal concen trations of either drug. When cells were transferred to drug-free medium after 4-hr exposures, vinblastine was released much more rapidly from cells than was Vincristine, and by 0.5 hr after resuspension of cells, the amount of Vincristine associated with the cells was greater than the amount of vinblastine and remained so for up to at least 6 hr.

APA, Harvard, Vancouver, ISO, and other styles

31

Gonzalez, H. A. "Pleurodesis with systemic chemotherapy in cancer patients." Journal of Clinical Oncology 27, no. 15_suppl (May 20, 2009): e20688-e20688. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.e20688.

Full text

Abstract:

e20688 Background: Pleural effusions are a common complication in cancer. All tumors, except CNS tumors, can produce pleural effusions. Pleural effusions are usually caused by direct tumor pleural involvement. Diagnosis is clinical and paraclinical. In cancer patients, in pneumonia absence, most of pleural effusions are malignant, regardless cytology results. Among different treatment modalities, chemical pleurodesis is the oftenest, but it is not etiologic nor physiologic. Chemotherapy in chemosensitive cancers is a good management approach. The objective of this study was measure systemic chemotherapy effectiveness in cancer pleural effusion after drainage and emphasize this method as treatment. Methods: Beginning 1/March/2001 and finalizing 30/July/2006, patients with chemosensitive cancers, malignant pleural effusions, no previous chemotherapy, KI > 80, life expectancy > 6 months, were included. Procedure: Chest X - ray, chest tube insertion for draining pleural effusion, systemic chemotherapy application, generally IV, tube remotion the day after ending chemotherapy, clinical and paraclinical follow up. No effusion reproduction minimum per six months. Effectiveness goal was 80% minimum. General statistic analysis was used. Results: 42 patients were studied, male: 38,09%, female: 61,91%. Median age: 59. Cancers: bronchogenic carcinoma: 42,8%, breast carcinoma: 28,5%, ovarian carcinoma: 14,2 %, carcinoma of unknown origin: 9,52%, others: 4,76%. Clinical stages: III B: 57,2%, most of them bronchogenic carcinoma, IV: 42,8%. Total effectiveness: 85,7%. Effectiveness in known origin cancers: 92,1%. Effectiveness in unknown origin cancers: 25%. Pleural effusion recurrence 14,3%. Drugs employed in appropriate drug regimens: cisplatin, carboplatin, etoposide, gemcitabine, vinorelbine, cyclophosphamide, doxorubicin, docetaxel, capecitabine. Conclusions: Systemic chemotherapy after draining effusions is a good approach for treating chemosensitive cancer pleural effusions, because can produce pleurodesis, is etiologic, has a high effectiveness and can improve survival. No significant financial relationships to disclose.

APA, Harvard, Vancouver, ISO, and other styles

32

Middleton, Justin, Daniel Stover, and Tsonwin Hai. "Chemotherapy-Exacerbated Breast Cancer Metastasis: A Paradox Explainable by Dysregulated Adaptive-Response." International Journal of Molecular Sciences 19, no. 11 (October 26, 2018): 3333. http://dx.doi.org/10.3390/ijms19113333.

Full text

Abstract:

An emerging picture in cancer biology is that, paradoxically, chemotherapy can actively induce changes that favor cancer progression. These pro-cancer changes can be either inside (intrinsic) or outside (extrinsic) the cancer cells. In this review, we will discuss the extrinsic pro-cancer effect of chemotherapy; that is, the effect of chemotherapy on the non-cancer host cells to promote cancer progression. We will focus on metastasis, and will first discuss recent data from mouse models of breast cancer. Despite reducing the size of primary tumors, chemotherapy changes the tumor microenvironment, resulting in an increased escape of cancer cells into the blood stream. Furthermore, chemotherapry changes the tissue microenvironment at the distant sites, making it more hospitable to cancer cells upon their arrival. We will then discuss the idea and evidence that these devastating pro-metastatic effects of chemotherapy can be explained in the context of adaptive-response. At the end, we will discuss the potential relevance of these mouse data to human breast cancer and their implication on chemotherapy in the clinic.

APA, Harvard, Vancouver, ISO, and other styles

33

Gupta, Satya P. "Molecular Processes in Cancers and Cancer Chemotherapy." Current Chemical Biology 15, no. 1 (April 27, 2021): 4. http://dx.doi.org/10.2174/221279681501210407102624.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Kris, Mark G., Matthew D. Hellmann, and Jamie E. Chaft. "Chemotherapy for Lung Cancers: Here to Stay." American Society of Clinical Oncology Educational Book, no. 34 (May 2014): e375-e380. http://dx.doi.org/10.14694/edbook_am.2014.34.e375.

Full text

Abstract:

Four decades of clinical research document the effectiveness of chemotherapy in patients with lung cancers. Chemotherapeutic agents can improve lung cancer symptoms, lengthen life in most patients with lung cancers, and enhance curability in individuals with locoregional disease when combined with surgery or irradiation. Chemotherapy's effectiveness is enhanced in patients with EGFR-mutant and ALK-positive lung cancers and can “rescue” individuals whose oncogene-driven cancers have become resistant to targeted agents. As immunotherapies become part of the therapeutic armamentarium for lung cancers, chemotherapeutic drugs have the potential to modulate the immune system to enhance the effectiveness of immune check point inhibitors. Even in this era of personalized medicine and targeted therapies, chemotherapeutic agents remain essential components in cancer care.

APA, Harvard, Vancouver, ISO, and other styles

35

Kubota, Tetsuro. "Adjuvant Cancer Chemotherapy of Gactric Cancer." Japanese Journal of Gastroenterological Surgery 31, no. 8 (1998): 1936–40. http://dx.doi.org/10.5833/jjgs.31.1936.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Lowe, Thomas, and Robert J. Morgan. "Intraperitoneal Chemotherapy of Ovarian Cancer." Women's Health 3, no. 4 (July 2007): 433–40. http://dx.doi.org/10.2217/17455057.3.4.433.

Full text

Abstract:

Ovarian cancer is the leading cause of death among cancers of the female reproductive tract. Most women present with regionally advanced intraperitoneal disease with superficial spread of tumor along the peritoneal surfaces. Distant metastasis rarely occurs until late in the disease process; however, long-term survival of patients with advanced disease remains poor. Intraperitoneal chemotherapy allows higher concentration and prolonged half-life of chemotherapy within the peritoneal cavity compared with intravenous administration, while therapeutic intravenous concentrations are obtained. Three large randomized Phase III trials and a meta-analysis have firmly established the superiority of combination intraperitoneal and intravenous chemotherapy compared with intravenous chemotherapy alone in women with optimally debulked advanced epithelial ovarian carcinoma. In January of 2006, the National Cancer Institute issued a clinical alert recommending that these women receive a combination of intravenous and intraperitoneal chemotherapy; however, resistance to adopt this as a new standard of care results from concerns regarding toxicity and lack of experience with intraperitoneal catheters. Here we review the largest trials of combination intraperitoneal and intravenous chemotherapy, address the concerns regarding intraperitoneal chemotherapy, and provide further resources for implementing intraperitoneal chemotherapy into practice.

APA, Harvard, Vancouver, ISO, and other styles

37

Siracusano, Salvatore, Riccardo Rizzetto, and Antonio Benito Porcaro. "Bladder cancer genomics." Urologia Journal 87, no. 2 (January 16, 2020): 49–56. http://dx.doi.org/10.1177/0391560319899011.

Full text

Abstract:

Until recently, the treatment of bladder cancer, for several years, was limited to surgery and to immunotherapy or chemotherapy. Currently, the extensive analysis of molecular alterations has led to novel treatment approaches. The advent of polymerase chain reaction and genomic hybridization techniques has allowed to investigate alterations involved in bladder cancer at DNA level. By this way, bladder cancers can be classified as papillary or non-papillary based on genetic alterations with activation or mutations in FGFR3 papillary tumors and with inactivation or mutations involving TP53 and RB1 in non-papillary tumors. Recently, the patterns of gene expression allow to differentiate basal and luminal subtypes as reported in breast cancer. In particular, basal cancers are composed of squamous and sarcomatoid pathological findings, while luminal cancers are composed of papillary finding features and genetic mutations (FGFR3). In particular, specific investigative studies demonstrated that luminal cancers are associated with secondary muscle invasive cancer while basal tumors are related to advanced disease since they are often metastatic at diagnosis. Moreover, from therapeutic point of view, different researchers showed that mutations of DNA are related to the sensitivity of bladder cancer while performing cisplatin chemotherapy. In this prospective, the bladder cancer molecular subtyping classification might allow identifying the set of patients who can safely avoid neoadjuvant chemotherapy likely because of the low response to systemic chemotherapy (chemoresistant tumors). In this context, the Cancer Genome Atlas (TCGA) project has improved the knowledge of the molecular targets of invasive urothelial cancers allowing the researchers to propose hypothesis suggesting that agents targeting the genomic alterations may be an effective strategy in managing these cancers, which occur in about 68% of muscle invasive cancers. A future goal will be to combine treatment strategies of invasive bladder cancers according to their genetic mutational load defined by molecular pathology.

APA, Harvard, Vancouver, ISO, and other styles

38

Sternberg, Cora N., S. Machele Donat, Joaquim Bellmunt, Randall E. Millikan, Walter Stadler, Pieter De Mulder, Amir Sherif, Hans von der Maase, Taiji Tsukamoto, and Mark S. Soloway. "Chemotherapy for Bladder Cancer: Treatment Guidelines for Neoadjuvant Chemotherapy, Bladder Preservation, Adjuvant Chemotherapy, and Metastatic Cancer." Urology 69, no. 1 (January 2007): 62–79. http://dx.doi.org/10.1016/j.urology.2006.10.041.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Ng, Weng, Susannah Jacob, Geoff Delaney, Viet Do, and Michael Barton. "Estimation of an Optimal Chemotherapy Utilisation Rate for Upper Gastrointestinal Cancers: Setting an Evidence-Based Benchmark for the Best-Quality Cancer Care." Gastroenterology Research and Practice 2015 (2015): 1–10. http://dx.doi.org/10.1155/2015/753480.

Full text

Abstract:

Aims. The proportion of patients with upper gastrointestinal cancers that received chemotherapy varies widely in Australia and internationally, indicating a need for a benchmark rate of chemotherapy utilisation. We developed evidence-based models for upper gastrointestinal cancers to estimate the optimal chemotherapy utilisation rates that can serve as useful benchmarks for measuring and improving the quality of care.Materials and Methods. Optimal chemotherapy utilisation models for cancers of the oesophagus, stomach, pancreas, gallbladder, and primary liver were constructed using indications for chemotherapy identified from evidence-based guidelines.Results. Based on the best available evidence, the optimal proportion of upper gastrointestinal cancers that should receive chemotherapy at least once during the course of the patients’ illness was estimated to be 79% for oesophageal cancer, 83% for gastric cancer, 35% for pancreatic cancer, 80% for gallbladder cancer, and 27% for primary liver cancer.Conclusions. The reported chemotherapy utilisation rates for upper gastrointestinal cancers (with the exception of primary liver cancer) appear to be substantially lower than the estimated optimal rates suggesting that chemotherapy may be underutilised. Further studies to elucidate the reasons for the potential underutilisation of chemotherapy in upper gastrointestinal tumours are required to bridge the gap between the ideal and actual practice identified.

APA, Harvard, Vancouver, ISO, and other styles

40

Barbosa, Rafael Fernando Mendes, Bruna Francielle Toneti, Juliana Maria de Paula Avelar, Amanda Fonseca Baviera, Liyoko Okino, and Namie Okino Sawada. "Incidence of neutropenia induced by chemotherapy in the treatment of colorectal cancer." Revista da Rede de Enfermagem do Nordeste 20 (April 3, 2019): e33884. http://dx.doi.org/10.15253/2175-6783.20192033884.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Akinsal, Emrecan, and Mustafa Sofikerim. "Prostate Cancer and Chemotherapy." Türk Üroloji Seminerleri/Turkish Urology Seminars 1, no. 7 (November 1, 2010): 207–10. http://dx.doi.org/10.5152/tus.2010.29.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Yoon, Sung Soo, and Noe Kyeong Kim. "Chemotherapy of Laryngeal Cancer." Journal of Clinical Otolaryngology Head and Neck Surgery 2, no. 2 (November 1991): 149–58. http://dx.doi.org/10.35420/jcohns.1991.2.2.149.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Hong, Yong Sang, and Tae Won Kim. "Chemotherapy for Colorectal Cancer." Journal of the Korean Medical Association 53, no. 7 (2010): 582. http://dx.doi.org/10.5124/jkma.2010.53.7.582.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Lim, Myong Cheol, and Sang-Yoon Park. "Chemotherapy for ovarian cancer." Journal of the Korean Medical Association 59, no. 3 (2016): 175. http://dx.doi.org/10.5124/jkma.2016.59.3.175.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Bang, Yung Jue. "Chemotherapy for Colorecal Cancer." Journal of the Korean Medical Association 45, no. 7 (2002): 833. http://dx.doi.org/10.5124/jkma.2002.45.7.833.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Park, Keunchil. "Chemotherapy in Lung Cancer." Journal of the Korean Medical Association 46, no. 1 (2003): 38. http://dx.doi.org/10.5124/jkma.2003.46.1.38.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Alberts, Steven R. "Cancer Chemotherapy Pocket Guide." Mayo Clinic Proceedings 73, no. 12 (December 1998): 1229–30. http://dx.doi.org/10.4065/73.12.1229-b.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Lidbrink, Elisabet, and Jonas Bergh. "Chemotherapy of Breast Cancer." American Journal of Cancer 1, no. 3 (2002): 165–71. http://dx.doi.org/10.2165/00024669-200201030-00001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

MATSUMURA, Yasuhiro. "Cancer Chemotherapy by DDS." Oleoscience 10, no. 1 (2010): 25–30. http://dx.doi.org/10.5650/oleoscience.10.25.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Sastre, Javier, Jose Angel García-Saenz, and Eduardo Díaz-Rubio. "Chemotherapy for gastric cancer." World Journal of Gastroenterology 12, no. 2 (2006): 204. http://dx.doi.org/10.3748/wjg.v12.i2.204.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!